Study to Evaluate the Effect of CIN-107 on the Pharmacokinetics of the MATE Substrate, Metformin, in Healthy Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

27 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-28

Study Completion Date

2020-12-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, open-label, two-period, crossover Phase 1 to assess the impact of CIN-107 on the pharmacokinetics (PK) of metformin and the safety and tolerability of coadministration of CIN-107 and metformin as compared to metformin alone.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy Participants

NCT05550129

Healthy Volunteers

COMPLETED PHASE1

A Pharmacokinetic Evaluation of Metformin in Relation to the Polymorphism A270S in Healthy Caucasian Volunteers

NCT01237522

Metformin Organic Cation Transporter 2 Polymorphism,Single Nucleotide

COMPLETED PHASE4

Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers

NCT01405118

Rheumatoid Arthritis

COMPLETED PHASE1

A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years

NCT07216131

Healthy Participants

COMPLETED PHASE1

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02865668

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment A: Immediate-release metformin

Treatment A: single 1000 mg dose of immediate-release metformin

Subjects will be randomly assigned to 1 of 2 sequences: AB or BA.

* Treatment A: a single 1000 mg dose of immediate-release metformin; and
* Treatment B: a single 1000 mg dose of immediate-release metformin coadministered with a 10 mg dose of CIN-107.

All study medication will be administered at 8:00 AM (±2 hours). There will be a minimum 10-day washout between administration of study drug in each treatment period.

Group Type ACTIVE_COMPARATOR

Metformin

Intervention Type DRUG

1000 mg dose of immediate-release metformin

Treatment B: Immediate-release metformin coadministered with a CIN-107

Treatment B: a single 1000 mg dose of immediate-release metformin coadministered with a 10 mg dose of CIN-107

Subjects will be randomly assigned to 1 of 2 sequences: AB or BA.

* Treatment A: a single 1000 mg dose of immediate-release metformin; and
* Treatment B: a single 1000 mg dose of immediate-release metformin coadministered with a 10 mg dose of CIN-107.

All study medication will be administered at 8:00 AM (±2 hours). For Treatment B, the dose of CIN-107 will be administered 2 hours prior to the dose of metformin.

There will be a minimum 10-day washout between administration of study drug in each treatment period.

Group Type EXPERIMENTAL

Metformin

Intervention Type DRUG

1000 mg dose of immediate-release metformin

CIN-107

Intervention Type DRUG

10 mg dose of CIN-107

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metformin

1000 mg dose of immediate-release metformin

Intervention Type DRUG

CIN-107

10 mg dose of CIN-107

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy subjects between the ages of 18 and 55 years, inclusive, at Screening;
* Body mass index between 18 and 30 kg/m2, inclusive;
* In good health based on medical/surgical and psychiatric history, physical examination, electrocardiogram (ECG), vital signs (seated and orthostatic), and routine laboratory tests (serum chemistry, hematology, and urinalysis);
* Normal renal function, defined as estimated glomerular filtration rate ≥85 mL/min/1.73 m2 at Screening and Day -1;
* Nonsmokers who have not used nicotine-containing products (ie, cigarettes, nicotine patch, nicotine chewing gum, or electronic cigarettes) for at least 6 months prior to Screening;

Exclusion Criteria

* Actively participating in an experimental therapy study; received experimental therapy with a small molecule other than CIN-107 within 30 days of the first dose of study drug or 5 half-lives, whichever is longer; or received experimental therapy with a large molecule within 90 days of the first dose of study drug or 5 half-lives, whichever is longer;
* A personal or family history of long QT syndrome, Torsades de Pointes, other complex ventricular arrhythmias, or family history of sudden death;
* History of, or current, clinically significant arrhythmias, as judged by the Investigator, including ventricular tachycardia, ventricular fibrillation, atrial fibrillation, sinus node dysfunction, or clinically significant heart block. Subjects with minor forms of ectopy (eg, premature atrial contractions) are not necessarily excluded and may be discussed with the Medical Monitor for inclusion;
* Prolonged QT interval corrected by Fridericia's formula (\>450 msec);
* Seated systolic blood pressure (BP) \>140 mmHg and/or diastolic BP \>90 mmHg or systolic BP \<90 mmHg and/or diastolic BP \<50 mmHg;
* Postural tachycardia (ie, \>30 bpm upon standing) or orthostatic hypotension (ie, a fall in systolic BP ≥20 mmHg or diastolic BP ≥10 mmHg upon standing);
* Serum potassium \>upper limit of normal (ULN) of the reference range and serum sodium \<lower limit of normal of the reference range;
* Aspartate aminotransferase, alanine aminotransferase, or total bilirubin values \>1.2 × ULN;
* Positive for human immunodeficiency virus antibody, hepatitis C virus antibody, hepatitis B surface antigen, or severe acute respiratory syndrome coronavirus 2 RNA;
* Evidence or history of any clinically significant immunologic, hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, musculoskeletal, hepatic, psychiatric, neurologic, or allergic (including clinically significant or multiple drug allergies) disease; surgical conditions; cancer (with the exception of basal or squamous cell carcinoma of the skin and cancer that has resolved or has been in remission for \>5 years prior to Screening); or any condition that, in the Investigator's opinion, may confound study procedures or results, impact subject safety, or interfere with the absorption, distribution, metabolism, or excretion of the study drug (appendectomy allowed, cholecystectomy prohibited);
* Typical consumption of ≥14 alcoholic drinks weekly; Note: 1 drink of alcohol is equivalent to ½ pint of beer (285 mL), 1 glass of spirits (25 mL), or 1 glass of wine (125 mL).
* Surgical procedures within 4 weeks prior to Check-In (other than minor cosmetic surgery or minor dental procedures) or planned elective surgery during the treatment period;

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes